^
Association details:
| Biomarker: | Low MLR |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Systemic Inflammatory Biomarkers Predict Survival of Patients Treated With Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
Published date:
09/06/2023
Excerpt:
Similar to NLR, MLR can also predict OS and PFS in mRCC patients with different TKI drugs sunitinib and sorafenib; a low MLR correlated with better OS and PFS in the sorafenib group (P = .0086 and P = .0110, Figure 2(C) and (D)). The same result was observed in the sunitinib group, where low MLR correlated with better OS and PFS in patients with mRCC (P = .0446 and P = .0255, Figure 2(E) and (F)).
DOI:
https://doi.org/10.1177/1073274823119751
